Chengdu Suncadia Medicine Co., Ltd.
Clinical trials sponsored by Chengdu Suncadia Medicine Co., Ltd., explained in plain language.
-
New drug HRS-1635 targets tough blood cancers in early trial
Disease control Not yet recruitingThis early-phase study tests a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. The main goal is to check the drug's safety and find the best dose. Researchers will also see if it helps shrink tumors, but this is …
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 11:21 UTC
-
New hope for kidney disease: HRS-5965 aims to slow IgA nephropathy
Disease control Not yet recruitingThis study tests the long-term safety of an experimental drug, HRS-5965, in 380 adults with primary IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine and help preserve kidney function over time. Participants must have completed a pr…
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New heart failure drug HRS-5765 put to first safety test in humans
Knowledge-focused Not yet recruitingThis early-stage study tests a new medicine called HRS-5765 in 74 healthy adults to see if it is safe and how the body processes it. Participants will take single or multiple doses of the drug or a placebo. The goal is to gather safety and drug-level information, not to treat any…
Phase: PHASE1 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Knowledge-focused
Last updated May 26, 2026 11:27 UTC